<DOC>
	<DOCNO>NCT00920296</DOCNO>
	<brief_summary>The primary objective study compare steady-state plasma PK , safety tolerability GSK1265744 without etravirine</brief_summary>
	<brief_title>DDI Study Etravirine GSK1265744</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 50 year age . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) . Male subject must agree use one contraception method list protocol . Body weight &gt; =50 kg men &gt; =45 kg woman body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy drug/alcohol screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study . Has history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Pregnant female determine positive serum urine human chorionic gonadotrophin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PCTA ) clinically significant cardiac disease . History/evidence clinically significant pulmonary disease . History significant renal hepatic disease . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . Serum creatinine value great upper limit normal . Serum ALT , , AST , alkaline phosphatase bilirubin &gt; 1.5x upper limit normal . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . Exclusion criterion screen ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>drug interaction</keyword>
	<keyword>integrase inhibitor</keyword>
</DOC>